Evidence map›Paper›PMID 33361292›Full record

ArticleAntimicrobial agents and chemotherapy2021

Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study.

Shu-Yung Lin, Jia-Yih Feng, Chih-Yuan Lee, Yi-Chih Lin, Yu-Hsiang Chou, Kuan-Yin Lin, Yu-Feng Wei, Shu-Wen Lin, Chin-Hao Chang, Ping-Huai Wang and 3 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shu-Yung LinDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Jia-Yih FengDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chih-Yuan LeeDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Yi-Chih LinDepartment of Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan.
Yu-Hsiang ChouDepartment of Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan.
Kuan-Yin LinDepartment of Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan.
Yu-Feng WeiDivision of Chest Medicine, Department of Internal Medicine, E-Da Hospital, Kaohsiung City, Taiwan.
Shu-Wen LinGraduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.
Chin-Hao ChangDepartment of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Ping-Huai WangDivision of Pulmonology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan pinghuaiwang@gmail.com ccshu@ntu.edu.tw.
Chin-Chung ShuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan pinghuaiwang@gmail.com ccshu@ntu.edu.tw.ORCID 0000-0003-0311-5148
Jann-Yuan WangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-3406-366X
Chong-Jen YuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We prospectively enrolled dialysis patients for LTBI intervention from three medical centers in Taiwan. LTBI treatments were 3 months of weekly rifapentine plus isoniazid (3HP) and 9 months of daily isoniazid (9H). Completion rate, ADE, and reasons for treatment termination were recorded. Factors associated with treatment termination and ADE were analyzed using multivariate logistic regression. In all, 91 treatment courses (41 9H and 50 3HP) were surveyed. The completion rates were 61% for 9H and 82% for 3HP (

Indexed as

Drug-Related Side Effects and Adverse ReactionsLatent TuberculosisAntitubercular AgentsDrug Therapy, CombinationHumansIsoniazidProspective StudiesRenal DialysisTaiwanAntitubercular AgentsIsoniaziddialysisdrug-related side effects and adverse reactionsinterferon gamma release testslatent tuberculosis

Identifiers

PMID33361292
PMCPMC8092540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.